Status: Recruiting
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without \[adjuvant\], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.
Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: ExpreS2ion BiotechnologiesUpdated: Apr 13, 2026Locations: 3
Eligibility criteria
Patients aged ≥18 years at screening visit. [+8]
Any planned intravenous chemotherapy regimens or check point inhibitors, or prev... [+15]